Challenges for Measuring Cost-effectiveness of Immunotherapy in Unresectable Hepatocellular Carcinoma

Mené dans un contexte américain, cette étude compare le rapport coût-efficacité du sorafénib et d'un traitement de première ligne combinant atézolizumab et bévacizumab chez des patients atteints d'un carcinome hépatocellulaire de stade métastatique ou non résécable

Résumé en anglais

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a significant and growing cause of cancer-related death in the United States.1 HCC prognosis markedly differs by tumor stage at diagnosis.2 Patients with advanced tumor burden usually have a poor prognosis, with median survival of 1 to 2 years.1 Evidence-based treatments are limited for advanced HCC, but recent advances have resulted in an increase in the use of immunotherapeutic agents. Among these are atezolizumab and bevacizumab, fully humanized monoclonal antibodies selectively targeting programmed cell death ligand 1 (PD-L1) and vascular endothelial growth factor, respectively.